New
The Associated Press Posted: Feb 29, 2016 9:03 AM ET Last Updated: Feb 29, 2016 9:03 AM ET
Shares of Valeant Pharmaceuticals plunged in premarket trading, amid ongoing turmoil over the embattled drugmaker's delayed financial results and its leader's health.
Even news Sunday that CEO Michael Pearson is returning after nine weeks recovering from pneumonia couldn't buoy Valeant shares.
They fell 6.1 percent to $75.74 in premarket trading Monday about an hour before the market open.
Investors, relieved over the end of the mystery about Pearson's status, are again focusing on Valeant's delayed financial results and future expectations.
Valeant was to have publicly released preliminary fourth-quarter and 2015 results and discussed 2016 prospects om Monday. Now it says it will do so "in the near term." It also has withdrawn all its financial forecasts.
Last week, Valeant said it wouldn't file results with regulators until in resolves questions about how some revenue was recorded.
Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.
Submission Policy
Note: The CBC does not necessarily endorse any of the views posted. By submitting your comments, you acknowledge that CBC has the right to reproduce, broadcast and publicize those comments or any part thereof in any manner whatsoever. Please note that comments are moderated and published according to our submission guidelines.
0 nhận xét:
Đăng nhận xét